Artículos científicos publicados por los investigadores del Barcelonaβeta Brain Research Center (BBRC), relacionados con la enfermedad de Alzheimer, neuroimagen, memoria y enfermedades neurodegenerativas, entre otros campos.
Blazhenets G, Soleimani-Meigooni DN, Chiotis K, Allen IE, Rabinovici GD, La Joie R; Meta-Centiloid Study Group; Apostolova LG, Asken BM, Bejanin A, Benzinger TLS, Betthauser TJ, Bluma M, Bombois S, Bourgeat P, Bouteloup V, Braskie MN, Brendel M, Brickman AM, Bryant N, Bullich S, Carrillo MC, Casaletto K, Cash DM, Chang CC, Chang HI, Chao Y, Chêne G, Chételat G, Coath W, Collij LE, Colmant L, Corrada MM, Craft S, Dickerson BC, Dubois B, Dufouil C, Fajardo A, Farrar G, Fortea J, Frings L, Frisoni GB, Gardner RC, Garibotto V, Gnörich JS, Gordon BA, Gu Y, Guan Y, Guo T, Hanseeuw BJ, Hansson O, Harrison TM, Huang Q, Huang SH, Iaccarino L, Ishii K, Ishi K, Jagust WJ, Johnson SC, Kato T, Katsumi Y, Kaye J, Koeppe RA, Kolinger GD, Kramer JH, Landau SM, Landeau B, Lao PJ, Lee S, Lleó A, Lopresti BJ, Lowe VJ, Luchsinger JA, Malpetti M, Mao X, March A, Masters CL, Meyer PT, Mezenge F, Mormino EC, Franquesa-Mullerat M, Nakamura A, Nordberg A, O'Brien JT, O'Bryant SE, Pappas I, Peretti DE, Quenon L, Rowe CC, Rowe JB, Rudolph MD, Salvadó G, Schott JM, Schwartz DL, Schwarz CG, Seo SW, Shekari M, Silbert LC, Smith R, Snyder HM, Sokolowski A, Sperling RA, Sun P, Taggett JZ, Toga AW, Touroutoglou A, Vaillancourt DE, van de Giessen E, Vijverberg J, Vemuri P, Villain N, Villemagne VL, Villeneuve S, Wang WE, Weiner M, Woodworth D, Xiao C, Xie F, Yoon Y, Young CB, Yun M; A4, ABIDE, ADNI*, ADNI-DoD, AgeWell, AIBL, AMYPAD, BACS, BATON, BIOCARD, BLSA, BioFINDER-2, BrANCH, CPAS, DETECT-AD, GEMS, GHABS, HABS, HABS-HD, IDEAS, IMAP, INSIGHT-preAD, Insight46, K-ROAD, LEADS, MCSA, MULNIAD, MEMENTO, SCAN, PREVENT-AD, SPIN, Severanc.
Importance: Amyloid positron emission tomography (PET) is increasingly used in research and clinical settings to determine the etiology of cognitive decline and eligibility for amyloid-targeting...
Pieperhoff L, Lorenzini L, Almeida F, Tranfa M, Bollack A, Arunachalam P, Masserini F, Wolz R, Grootoonk S, Ritchie C, Boada M, Marquié M, Vijverberg J, Vandenberghe R, Hanseeuw BJ, Martinez-Lage P, Payoux P, Visser PJ, Schöll M, Frisoni GB, Pardini M, Roccataglia L, Stephens AW, Buckley C, Farrar G, Jessen F, Gispert JD, Salvadó G, Luckett ES, Mutsaerts HM, Wink AM, Collij LE, Barkhof F, Oliveira TG; AMYPAD consortium.
Introduction: Early Alzheimer's disease (AD) involves subtle cortical changes that may precede atrophy. Magnetic resonance imaging (MRI) microstructural markers may detect earlier pathology than...
Gallay C, Soldevila-Domenech N, López-Martos D, Sanchez-Benávides G, Huguet J, Suárez-Calvet M, Gispert JD, Salvadó G, Sundermann EE, Grau-Rivera O, Brugulat-Serrat A; for ALFA study.
Background and objectives: Epidemiologic studies exploring the effect of parity on Alzheimer disease (AD) yield mixed results, and little is known about how parity may modify the impact of AD...
López-Martos D, Suárez-Calvet M, Salvadó G, Cacciaglia R, Shekari M, González-Escalante A, Horta-Barba A, Palma-Gudiel H, Milà-Alomà M, Brugulat-Serrat A, Minguillon C, Tonietto M, Borroni E, Klein G, Quijano-Rubio C, Kollmorgen G, Zetterberg H, Blennow K, Gispert JD, Sánchez-Benavides G, Grau-Rivera O; ALFA study.
Alzheimer's disease (AD) diagnostic guidelines emphasize subjective cognitive decline (SCD) preceding mild cognitive impairment (MCI), implicitly assuming awareness of cognitive decline (ACD) is...
Arunachalam P, Pieperhoff L, Lorenzini L, Tranfa M, Masserini F, Treves F, Pontillo G, Preti MG, Broeders TAA, Schoonheim MM, Douw L, Ritchie C, Boada M, Marquié M, Visser PJ, Cacciaglia R, Gispert JD, Salvadó G, Luckett ES, Collij LE, Cole JH, Barkhof F, Wink AM; AMYPAD consortium.
Background: Structural pathways of the brain facilitate functional communication, and their disruption in preclinical Alzheimer's disease may reflect network vulnerability and compensatory brain...
López-Martos D, Cacciaglia R, Suárez-Calvet M, Salvadó G, Shekari M, González-Escalante A, Milà-Alomà M, Brugulat-Serrat A, Minguillon C, Tonietto M, Borroni E, Klein G, Quijano-Rubio C, Kollmorgen G, Zetterberg H, Blennow K, Gispert JD, Grau-Rivera O, Sánchez-Benavides G; ALFA study.
Background: The objective of this study was to provide a multimodal biomarker characterization of amnestic objective subtle cognitive decline (obj-SCD) in aging and preclinical Alzheimer's disease (AD...
Salvadó G, Horie K, Barthélemy NR, Schindler SE, Janelidze S, Orduña Dolado A, Bali D, Perrin RJ, Morris JC, Benzinger TLS, Gordon BA, Stomrud E, Mattsson-Carlgren N, Palmqvist S, Vogel JW, Bateman RJ, Ossenkoppele R, Hansson O
Importance: Biological staging of Alzheimer disease (AD) can improve diagnostic accuracy and prognostic assessment. However, existing approaches often require invasive procedures and specialized...
Shekari M, Escalante AG, Milà-Alomà M, Falcon C, López-Martos D, Sánchez-Benavides G, Brugulat-Serrat A, Niñerola-Baizán A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Montoliu-Gaya L, Snellman A, Day TA, Dage JL, Ortiz-Romero P, Tonietto M, Borroni E, Klein G, Kollmorgen G, Carboni M, Quijano-Rubio C, Vanmechelen E, Minguillón C, Fauria K, Perissinotti A, Molinuevo JL, Zetterberg H, Blennow K, Grau-Rivera O, Suárez-Calvet M, Gispert JD; ALFA Study.
Introduction: We examined neurofibrillary tangle (NFT) pathology using 18F-RO-948 tau positron emission tomography (PET) in cognitively unimpaired individuals and its associations with amyloid plaques...
Mattsson-Carlgren N, Palmqvist S, Horie K, Barthélemy N, Salvadó G, Binette AP, Tideman P, Morris JC, Benzinger TL, Perrin RJ, Janelidze S, Collij LE, Ossenkoppele R, Schindler SE, Stomrud E, Bateman RJ, Hansson O.
Background: Alzheimer's disease pathology can be accurately identified with blood biomarkers (core 1 biomarkers), including plasma p-tau217 tests. Biomarkers that change longitudinally after diagnosis...